Oppenheimer analysts downgraded healthcare stock CVS (CVS) - Get Report from outperform to perform on Monday, citing drug pricing headwinds and the company's unfavorable exposure to the managed-care business.

CVS shares were unaffected on Monday morning, however, rising 2% to $53.85. They are down almost 18% this year, however, compared to a gain of about 16% for the S&P 500. 

Oppenheimer removed its $85 price target for CVS, which was 64% above the stock's closing price on Friday. 

"We are looking to reset the bar on our CVS rating, as we view it as more of a long-term opportunity given the potential timeline to execute on its strategy and the near-term legacy business challenges," the analysts wrote. 

Oppenheimer said that the near-term challenge is that "we expect the drug-price noise out of Washington to continue for the foreseeable future. Shares of rival pharmacy firm Walgreens (WBA) - Get Report  have plummeted 15.8% since April 1, as the company posted disappointing guidance largely due to near-term drug pricing deterioration. 

Meanwhile, United Health (UNH) - Get Report shares fell 8.6% last week as Democratic presidential candidate Bernie Sanders announced a "medicare-for-all plan" that would create a single-payer health care system to replace the current employer-based system.

Related. Walgreens Stock Falls After Earnings, Guidance Disappoint

Oppenheimer analysts added that "we remain bullish on the overall managed care sector --particularly in light of the recent weakness in the group -- but CVS's exposure to the business is still quite modest, and we would prefer other names in the space right now," Oppenheimer said.

While CVS acquired Aetna for $71 billion in a deal that closed in late 2018, Oppenheimer notes that earnings from managed care operations will only account for roughly 31%, in the firm's own estimate, of CVS' total 2019 earnings. According to Oppenheimer, that suggests "CVS's fate will likely continue to ride on the pharmacy segments (69% combined), which we believe face less bullish prospects." 

The analysts said the full integration of Aetna will take long enough that there is currently insufficient visibility to justify a higher valuation. 

Oppenheimer is looking for full-year adjusted 2019 earnings per share of $6.75, a reduction from 2018's EPS result of $7.08. 

CVS and United Health are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells CVS or UNH? Learn more now.

Watch TheStreet's Behind the Label video series | More videos on our Youtube Channel